Molecular Templates, Inc.
MTEM evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Lead Asset:
- mt-0169 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for MTEM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
mt-0169 (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates · 1 clinical trial for Molecular Templates, Inc..
Run Molecular Templates, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Molecular Templates, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Molecular Templates, Inc.'s lead drug candidate?
Molecular Templates, Inc.'s most advanced tracked candidate is mt-0169 (Preclinical) for CD38+ leukemia.
Who is the CEO of Molecular Templates, Inc.?
Dr. Eric E. Poma Ph.D. is the chief executive officer of Molecular Templates, Inc. (MTEM).
Where is Molecular Templates, Inc. headquartered?
Molecular Templates, Inc. (MTEM) is headquartered in Austin, TX, United States.
What therapeutic areas does Molecular Templates, Inc. focus on?
Molecular Templates, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.